Abstract:Cancer represents the leading public health problem throughout the world. Globally, about one out of six deaths is related to cancer, which is largely due to the metastatic lesions. However, there are no effective strategies for targeting cancer metastasis. Identification of the key druggable targets maintaining metastasis is crucial for cancer treatment. In our recent study (Cai et al. (2020), Mol Cell, doi: 10.1016/j.molcel.2020.09.018), we found that activity of AMPK was enriched in metastatic tumors compared to primary tumors. Depletion of AMPK rendered cancer cells more sensitive to metabolic and oxidative stress, leading to the impairment of breast cancer lung metastasis. Activation of AMPK rewired cancer metabolism towards TCA cycle, which protects disseminated cancer cells from both metabolic and oxidative stress-induced cell death, and facilitates cancer metastasis. Further, AMPK critically maintained the activity of pyruvate dehydrogenase complex (PDH), the rate limiting enzyme involved in TCA cycle, thus favoring the pyruvate metabolism towards TCA cycle rather than converting it to lactate. Mechanistically, AMPK was shown to co-localize with PDHA, the catalytic subunit of PDH, in the mitochondrial matrix and directly triggered the phosphorylation of PDHA on Ser295 and Ser314. Hyper-phosphorylation of Ser295 and Ser314 of PDHA promotes lung metastasis through elevating activity of PDH. Of note, PDHA Ser314 phosphorylation abrogated the interaction between PDHA and PDHKs leading to the dephosphorylation on previously reported S293 site, whose phosphorylation serves as a negative signal for PDH activation, while S295 phosphorylation serves as an intrinsic catalytic site required for pyruvate metabolism. Our study presented the first evidence for the pro-metastatic property of the AMPK-PDH axis and advance our current understanding of how PDH is activated under physiological and pathological conditions.

Cellular energy stress induces AMPK-mediated regulation of glioblastoma cell proliferation by PIKE-A phosphorylation

The Critical Role of AMPK in Driving Akt Activation under Stress, Tumorigenesis and Drug Resistance

Phosphoinositide-3-Kinase Enhancers, PIKEs: Their Biological Functions and Roles in Cancer.

PI3K/Akt signal transduction pathway and tumor

Stabilization of Phosphofructokinase 1 Platelet Isoform by AKT Promotes Tumorigenesis

S6K1-mediated Phosphorylation of PDK1 Impairs AKT Kinase Activity and Oncogenic Functions

Revving the engine: PKB/AKT as a key regulator of cellular glucose metabolism

AMP‐activated Protein Kinase Regulates Cancer Cell Growth and Metabolism Via Nuclear and Mitochondria Events

AMPK Inhibition Suppresses the Malignant Phenotype of Pancreatic Cancer Cells in Part by Attenuating Aerobic Glycolysis

KIAA0101 knockdown inhibits glioma progression and glycolysis by inactivating the PI3K/AKT/mTOR pathway

Selective autophagy of AKAP11 activates cAMP/PKA to fuel mitochondrial metabolism and tumor cell growth

Phosphofructokinase 1 Platelet Isoform Promotes β-Catenin Transactivation for Tumor Development.

PCAF-mediated Akt1 Acetylation Enhances the Proliferation of Human Glioblastoma Cells

Amp-Activated Protein Kinase Induces A P53-Dependent Metabolic Checkpoint

PIK3R1 negatively regulates the epithelial-mesenchymal transition and stem-like phenotype of renal cancer cells through the AKT/GSK3β/CTNNB1 signaling pathway

Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells

Comprehensive RNAseq Analysis Reveals PIK3CD Promotes Glioblastoma Tumorigenesis by Mediating PI3K-Akt Signaling Pathway

AMPK maintains TCA cycle through sequential phosphorylation of PDHA to promote tumor metastasis

Ikbke Activates Akt Independent Of Phosphatidylinositol 3-Kinase/Pdk1/Mtorc2 To Sustain Malignant Transformation

Phosphatidylinositol 3-Kinase Affects Mitochondrial Function in Part Through Inducing Peroxisome Proliferator-Activated Receptor Γ Coactivator-1Β Expression.

Stabilization of AMPK/PFKL/RPIA in the Glycolytic Bodies Transduces IL6/STAT3 Signal in Hepatocarcinogenesis